3,528 results match your criteria European journal of heart failure[Journal]


Novel potassium binders as enabling therapy in heart failure.

Eur J Heart Fail 2019 Apr 16. Epub 2019 Apr 16.

Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.1474
Publisher Site
http://dx.doi.org/10.1002/ejhf.1474DOI Listing
April 2019
4 Reads

Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail 2019 Apr 16. Epub 2019 Apr 16.

Berlin-Brandenburg Center for Regenerative Therapies, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Berlin, Department of Cardiology, Campus Virchow Klinikum, Charite - Universitaetsmedizin Berlin, Berlin, Germany.

Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1461DOI Listing
April 2019
2 Reads
6.526 Impact Factor

The GUIDE-IT heart failure risk prediction model: another fish in the sea?

Eur J Heart Fail 2019 Apr 14. Epub 2019 Apr 14.

Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1472DOI Listing

Comparison of mortality in primary and secondary Takotsubo cardiomyopathy with severe left ventricular dysfunction.

Authors:
Lovely Chhabra

Eur J Heart Fail 2019 Apr 14. Epub 2019 Apr 14.

Heartland Regional Medical Center, Marion, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1470DOI Listing

Do we need aspirin in HeartMate 3 patients?

Eur J Heart Fail 2019 Apr 14. Epub 2019 Apr 14.

Vita-Salute San Raffaele University, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1468DOI Listing

Common laboratory parameters as indicators of multi-organ dysfunction in acute heart failure.

Eur J Heart Fail 2019 Apr 11. Epub 2019 Apr 11.

Baylor University Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1466DOI Listing
April 2019
1 Read

Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.

Eur J Heart Fail 2019 Apr 11. Epub 2019 Apr 11.

IQVIA Germany (IQVIA Commercial GmbH & Co. OHG), Frankfurt, Germany.

Aims: To analyse real-world treatment patterns of sacubitril/valsartan (sac/val) using data from a pharmacy database in Germany.

Methods And Results: A retrospective cohort study of 26 191 adult patients (aged ≥ 18 years) in the IMS® longitudinal prescriptions database in Germany who were dispensed sac/val from January 2016 to June 2017 was conducted. The analysis included sac/val dose titration assessed in the 6 months from first sac/val prescription; prescriptions of concomitant cardiovascular medications in the 6 months pre- and post-index and compliance and persistence during 12 months post-index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1465DOI Listing
April 2019
1 Read

Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it.

Eur J Heart Fail 2019 Apr 11. Epub 2019 Apr 11.

BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1463DOI Listing

April 2019 at a glance: prediction of heart failure, left atrial function, cardio-oncology.

Authors:
Marco Metra

Eur J Heart Fail 2019 Apr;21(4):393-394

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1260DOI Listing
April 2019
1 Read

Heart failure in arrhythmogenic cardiomyopathy: is phenotypic variability just a matter of genetics?

Eur J Heart Fail 2019 Apr 1. Epub 2019 Apr 1.

Cardiovascular Pathology Unit, Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padua, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1456DOI Listing

Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.

Eur J Heart Fail 2019 Apr 1. Epub 2019 Apr 1.

National Heart and Lung Institute, Imperial College London (Royal Brompton Hospital), London, UK.

Background: Physicians' adherence to guideline-recommended therapy is associated with short-term clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF). However, its impact on longer-term outcomes is poorly documented. Here, we present results from the 18-month follow-up of the QUALIFY registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1459DOI Listing

Exercise training in patients with a left ventricular assist device (Ex-VAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial.

Eur J Heart Fail 2019 Mar 28. Epub 2019 Mar 28.

Department of Internal Medicine and Cardiology, Charité University Medicine Berlin, Berlin, Germany.

Aims: Left ventricular assist device (LVAD) therapy is a promising option for patients with advanced heart failure (HF), refractory to guideline-mandated medical treatment either as a bridge to heart transplantation or as lifelong therapy. Functional capacity improves after LVAD implantation but remains reduced in patients with long-term LVAD therapy. Exercise training (ET) improves functional capacity and quality of life (QoL) in HF and may provide incremental benefits in patients supported with LVAD therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1431DOI Listing
March 2019
1 Read

Haemocompatibility-related adverse events are associated with a non-optimal haemodynamic profile during continuous-flow left ventricular assist device support: why it matters.

Authors:
Jerry D Estep

Eur J Heart Fail 2019 Mar 28. Epub 2019 Mar 28.

Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1457DOI Listing
March 2019
1 Read

Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction.

Eur J Heart Fail 2019 Mar 28. Epub 2019 Mar 28.

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Aims: Left atrial (LA) function is impaired in heart failure with preserved ejection fraction (HFpEF) and predicts disease severity and risk of adverse outcome. We sought to evaluate whether LA strain could enhance diagnosis of HFpEF.

Methods And Results: Consecutive patients with unexplained exertional dyspnoea and image quality suitable for measuring LA strain underwent invasive cardiopulmonary exercise testing to ascertain the presence of HFpEF or non-cardiac causes of dyspnoea (NCD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1464DOI Listing
March 2019
1 Read

Natriuretic peptides as a surrogate endpoint in clinical trials - a riddle wrapped in an enigma.

Eur J Heart Fail 2019 Mar 27. Epub 2019 Mar 27.

Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.1448
Publisher Site
http://dx.doi.org/10.1002/ejhf.1448DOI Listing
March 2019
2 Reads

Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.

Eur J Heart Fail 2019 Mar 27. Epub 2019 Mar 27.

Duke Clinical Research Institute, Durham, NC, USA.

Background: Most heart failure (HF) risk scores have been derived from cohorts of stable HF patients and may not incorporate up to date treatment regimens or deep phenotype characterization that change baseline risk over the short- and long-term follow-up period. We undertook the current analysis of participants in the GUIDE-IT (Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment) trial to address these limitations.

Methods And Results: The GUIDE-IT study randomized 894 high-risk patients with HF and reduced ejection fraction (≤ 40%) to biomarker-guided treatment strategy vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1450DOI Listing

Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction.

Eur J Heart Fail 2019 Mar 27. Epub 2019 Mar 27.

Division of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, MA, USA.

Aims: To assess whether natriuretic peptides (NPs) can be used to reliably predict long-term therapeutic effect on clinical outcomes for patients with heart failure and reduced ejection fraction (HFrEF).

Methods And Results: HFrEF intervention trials with mortality data were identified. Subsequently, we identified trials assessing therapy-induced changes in NPs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1411DOI Listing
March 2019
1 Read

Reply to letters on "The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology".

Eur J Heart Fail 2019 Mar 22. Epub 2019 Mar 22.

University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1462DOI Listing

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

Eur J Heart Fail 2019 Mar 21. Epub 2019 Mar 21.

Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.

Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseline and the effect of SGLT2 inhibitors on outcomes in individuals with established heart failure (with or without diabetes) is unknown.

Design And Methods: The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF) is an international, multicentre, parallel group, randomized, double-blind, study in patients with chronic heart failure, evaluating the effect of dapagliflozin 10 mg, compared with placebo, given once daily, in addition to standard care, on the primary composite outcome of a worsening heart failure event (hospitalization or equivalent event, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1432DOI Listing
March 2019
2 Reads

Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.

Eur J Heart Fail 2019 Mar 20. Epub 2019 Mar 20.

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Aims: Despite recent advances in the treatment of chronic heart failure (HF), mortality and hospitalizations still remain high. Additional therapies to improve mortality and morbidity are urgently needed. The efficacy of cardiac glycosides - although regularly used for HF treatment - remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1452DOI Listing
March 2019
1 Read
6.526 Impact Factor

The use of thiazide and thiazide-like diuretics in heart failure with congestion.

Eur J Heart Fail 2019 Mar 20. Epub 2019 Mar 20.

Heart Failure Working Group of the Spanish Society of Internal Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1455DOI Listing

How does neprilysin inhibition in heart failure work?

Eur J Heart Fail 2019 Mar 18. Epub 2019 Mar 18.

Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1454DOI Listing

Intravenous iron therapy in heart failure: a different perspective.

Eur J Heart Fail 2019 Mar 18. Epub 2019 Mar 18.

Feinberg Cardiovascular Research Institute, and Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1434DOI Listing

News from the American Heart Association: more on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure.

Eur J Heart Fail 2019 Mar;21(3):261-263

University Medical Center Belgrade, Belgrade, Serbia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1429DOI Listing
March 2019
1 Read

Figures of the Heart Failure Association: Andrew J. Stewart Coats, President-Elect, 2018-2020.

Authors:
Marco Metra

Eur J Heart Fail 2019 Mar;21(3):269-271

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1444DOI Listing

March 2019 at a glance: epidemiology and clinical trials.

Authors:
Marco Metra

Eur J Heart Fail 2019 Mar;21(3):259-260

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1258DOI Listing

Figures of the Heart Failure Association: Petar M. Seferović, President, 2018-2020.

Authors:
Andrew J S Coats

Eur J Heart Fail 2019 Mar;21(3):266-268

University of Warwick, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1430DOI Listing

Cardiomyopathy associated with long-term right ventricular pacing: an intriguing clinical issue.

Eur J Heart Fail 2019 Mar 12. Epub 2019 Mar 12.

Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1449DOI Listing

Mineralocorticoid receptor antagonists and acute heart failure.

Eur J Heart Fail 2019 Mar 12. Epub 2019 Mar 12.

Department of Internal Medicine, University Hospital Ramón y Cajal, University of Alcalá (IRYCIS), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1453DOI Listing

The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association.

Eur J Heart Fail 2019 Apr 12;21(4):402-424. Epub 2019 Mar 12.

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Ventricular-arterial coupling (VAC) plays a major role in the physiology of cardiac and aortic mechanics, as well as in the pathophysiology of cardiac disease. VAC assessment possesses independent diagnostic and prognostic value and may be used to refine riskstratification and monitor therapeutic interventions. Traditionally, VAC is assessed by the non-invasive measurement of the ratio of arterial (Ea) to ventricular end-systolic elastance (Ees). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1436DOI Listing
April 2019
4 Reads

Measurement of circulating natriuretic peptides to identify community-based patients at risk of incident heart failure - should we?

Authors:
Iain Squire

Eur J Heart Fail 2019 Apr 8;21(4):460-461. Epub 2019 Mar 8.

NIHR Biomedical Research Centre, University of Leicester, Leicester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1391DOI Listing

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.

Eur J Heart Fail 2019 Mar 6. Epub 2019 Mar 6.

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

Background: Secretion of adrenomedullin (ADM) is stimulated by volume overload to maintain endothelial barrier function, and higher levels of biologically active (bio-) ADM in heart failure (HF) are a counteracting response to vascular leakage and tissue oedema. This study aimed to establish the value of plasma bio-ADM as a marker of congestion in patients with worsening HF.

Methods And Results: The association of plasma bio-ADM with clinical markers of congestion, as well as its prognostic value was studied in 2179 patients with new-onset or worsening HF enrolled in BIOSTAT-CHF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1437DOI Listing
March 2019
6.526 Impact Factor

The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity.

Eur J Heart Fail 2019 Apr 6;21(4):519-528. Epub 2019 Mar 6.

Department of Translational Medical Sciences, 'Federico II' University, Naples, Italy.

Aims: Butyric acid (BUT), a short chain fatty acid produced daily by the gut microbiota, has proven beneficial in models of cardiovascular diseases. With advancements in cancer survival, an increasing number of patients are at risk of anticancer drug cardiotoxicity. Here we assess whether the novel BUT derivative phenylalanine-butyramide (FBA) protects from doxorubicin (DOXO) cardiotoxicity, by decreasing oxidative stress and improving mitochondrial function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1439DOI Listing
April 2019
2 Reads
6.526 Impact Factor

Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation.

Authors:
Milton Packer

Eur J Heart Fail 2019 Apr 6;21(4):398-401. Epub 2019 Mar 6.

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1447DOI Listing
April 2019
1 Read

Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?

Eur J Heart Fail 2019 Mar 4. Epub 2019 Mar 4.

Division of Core Clinical Laboratory Service, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1451DOI Listing

Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure.

Eur J Heart Fail 2019 Apr 3;21(4):537-539. Epub 2019 Mar 3.

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1441DOI Listing

Letter on 'Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation'.

Eur J Heart Fail 2019 Feb 27. Epub 2019 Feb 27.

Department of Cardiology, Montpellier University Hospital, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1446DOI Listing
February 2019
1 Read

Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.

Eur J Heart Fail 2019 Apr 27;21(4):529-535. Epub 2019 Feb 27.

Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.

Background: Trastuzumab improves dramatically the prognosis of HER2-positive breast cancer patients, but it may lead to cardiotoxicity with left ventricular (LV) systolic dysfunction. Its effects on right ventricular (RV) function have not however been elucidated. We sought to assess LV and RV deformation mechanics during treatment with trastuzumab in breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1385DOI Listing
April 2019
3 Reads

Heart failure risk reduction: is fit and overweight or obese better than unfit and normal weight?

Eur J Heart Fail 2019 Apr 27;21(4):445-448. Epub 2019 Feb 27.

Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1440DOI Listing
April 2019
6.526 Impact Factor

High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Eur J Heart Fail 2019 Feb 21. Epub 2019 Feb 21.

Centre de Référence Pour les Maladies Cardiaques Héréditaires, APHP, Hôpital de la Pitié Salpêtrière, Paris, France.

Background: Previous studies suggested that genetic status affects the clinical course of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) patients. The aim of this study was to compare the outcome of desmoglein-2 (DSG2) mutation carriers to those who carry the plakophilin-2 (PKP2) mutation, the most common ARVC/D-associated gene.

Methods And Results: Consecutive ARVC/D patients carrying a pathogenic mutation in PKP2 or DSG2 were selected from a national ARVC/D registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1423DOI Listing
February 2019

Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE).

Eur J Heart Fail 2019 Feb 20. Epub 2019 Feb 20.

Department of Cardiology and Cardiology Stem Cell Centre, Rigshospitalet University of Copenhagen, Copenhagen, Denmark.

Aims: Ischaemic heart failure (IHF) patients have a poor prognosis even with current guideline-derived therapy. Intramyocardial injections of autologous or allogeneic mesenchymal stromal cells might improve cardiac function leading to better clinical outcome.

Methods: The SCIENCE (Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE) consortium has initiated a Horizon 2020 funded multicentre phase II study in six European countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1412DOI Listing
February 2019
1 Read

Cardiorespiratory fitness, body mass index and heart failure incidence.

Eur J Heart Fail 2019 Apr 19;21(4):436-444. Epub 2019 Feb 19.

Cardiology Division, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.

Aims: Obesity is associated with increased risk of heart failure (HF). This risk may be modulated by improved cardiorespiratory fitness (CRF) as CRF is associated with favourable health outcomes. Thus, we assessed the interaction between body mass index (BMI), CRF and HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1433DOI Listing

Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

Eur J Heart Fail 2019 Apr 18;21(4):462-470. Epub 2019 Feb 18.

Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Aims: Klotho, an essential co-receptor for fibroblast growth factor (FGF)-23, has potentially beneficial inhibitory effects on the renin-angiotensin system. Limited data exist on the prognostic value of Klotho and FGF-23 levels in combination or their ability to predict benefit from angiotensin-converting enzyme (ACE) inhibition.

Methods And Results: A total of 3555 patients with stable ischaemic heart disease and left ventricular ejection fraction > 40% enrolled in the PEACE trial of trandolapril vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458082PMC

Individualizing surgical revascularization in patients with ischaemic heart failure - a further dive into STICHES.

Eur J Heart Fail 2019 Mar 18;21(3):382-384. Epub 2019 Feb 18.

Deparment of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1426DOI Listing